Mirati Therapeutics Inc
NASDAQ:MRTX
Mirati Therapeutics Inc
Revenue
Mirati Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mirati Therapeutics Inc
NASDAQ:MRTX
|
Revenue
$38.2m
|
CAGR 3-Years
46%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Mirati Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Mirati Therapeutics Inc
Breakdown by Segments
Mirati Therapeutics Inc
Total Revenue:
12.4m
USD
|
License And Collaboration Revenues:
11.7m
USD
|
Product Revenue, Net:
713k
USD
|
See Also
What is Mirati Therapeutics Inc's Revenue?
Revenue
38.2m
USD
Based on the financial report for Sep 30, 2023, Mirati Therapeutics Inc's Revenue amounts to 38.2m USD.
What is Mirati Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
32%
Over the last year, the Revenue growth was 224%. The average annual Revenue growth rates for Mirati Therapeutics Inc have been 46% over the past three years , 32% over the past five years .